(Q36349745)

13 August 2017

1 reference

title

The safety and efficacy of antithyroid drugs (English)

1 reference

13 August 2017

Fereidoun Azizi

1

1 reference

PubMed ID

16370960

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Drug Safety

13 August 2017

1 reference

13 August 2017

5

1 reference

13 August 2017

1

1 reference

13 August 2017

107-116

1 reference

Differences and Similarities in the Diagnosis and Treatment of Graves' Disease in Europe, Japan, and The United States

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Acute Effects of Corticosteroids on Thyroid Activity in Graves' Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Short-term treatment of Graves' disease with methimazole in high versus low doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Pharmacokinetic properties and bioavailability of methimazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug‐treated patients with Graves’ disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Antithyroid Drugs and Graves' Disease: A Prospective Randomized Evaluation of the Efficacy of Treatment Duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Long-term Antithyroid Treatment in Hyperthyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Liver tests in hyperthyroidism: effect of antithyroid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Liver transplantation for acute liver failure from drug induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Adverse effects of prenatal methimazole exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Thyroid function and intellectual development of children of mothers taking methimazole during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Prevention and treatment of postpartum Graves' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Thyroid function and intellectual development of infants nursed by mothers taking methimazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Thyroid function in breast-fed infants whose mothers take high doses of methimazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Transfer of drugs and other chemicals into human milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Has the use of antithyroid drugs for Graves' disease become obsolete?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

The Colorado thyroid disease prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

In VitroImmunoreactivity to Propylthiouracil, Methimazole, and Carbimazole in Patients with Graves’ Disease: A Possible Cause of Antithyroid Drug-Induced Agranulocytosis*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.107

Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study

21 January 2018

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1210/JCEM-50-1-144

Identifiers

DOI

10.1517/14740338.5.1.107

1 reference

13 August 2017

1 reference

PubMed ID

16370960